Virtue Capital Management LLC Buys 6,129 Shares of Illumina, Inc. $ILMN

Virtue Capital Management LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,129 shares of the life sciences company’s stock, valued at approximately $1,677,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Illumina in the 3rd quarter valued at approximately $17,487,000. ProShare Advisors LLC lifted its holdings in shares of Illumina by 165.8% during the 3rd quarter. ProShare Advisors LLC now owns 30,204 shares of the life sciences company’s stock worth $8,266,000 after acquiring an additional 18,841 shares during the period. Moss Adams Wealth Advisors LLC boosted its position in shares of Illumina by 8.7% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 1,394 shares of the life sciences company’s stock worth $382,000 after acquiring an additional 111 shares in the last quarter. MGO One Seven LLC boosted its position in shares of Illumina by 4.3% during the 3rd quarter. MGO One Seven LLC now owns 5,310 shares of the life sciences company’s stock worth $1,453,000 after acquiring an additional 217 shares in the last quarter. Finally, International Assets Investment Management LLC increased its stake in Illumina by 10,608.7% in the third quarter. International Assets Investment Management LLC now owns 55,257 shares of the life sciences company’s stock valued at $15,123,000 after acquiring an additional 54,741 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 2,061,235 shares of company stock worth $436,356,102. Insiders own 2.90% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Illumina Stock Performance

Shares of Illumina stock opened at $235.99 on Monday. The firm has a market capitalization of $35.63 billion, a PE ratio of 40.62, a price-to-earnings-growth ratio of 3.30 and a beta of 1.46. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The firm’s 50 day moving average is $249.30 and its 200 day moving average is $176.18. Illumina, Inc. has a 1 year low of $106.12 and a 1 year high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.34 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen boosted their price objective on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada raised their target price on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Stifel Nicolaus lifted their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Barclays boosted their price target on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Finally, Stephens downgraded Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective for the company. in a research report on Friday, October 23rd. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $238.53.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.